DAWNMIST (produit inactif : annulé après commercialisation : 30 juillet 2007)
Nonprescription drug in Canada (DIN); Cancelled after marketing: 30 July 2007
A nonprescription drug in Canada may have a cancelled status. Their presence does not demonstrate current sales. The DIN is the drug identification number printed on the packaging. The analysis indicates what the annexes to Regulation (EC) No 1223/2009 would require if this product were sold as a cosmetic in France. It does not assess its Canadian authorisation and does not constitute authorisation for sale in France. Only active ingredients are published in these extracts; the full formula and other conditions of use remain to be checked. No strength is estimated.
Drug Product Database, Canadian non-prescription drugs with cosmetic uses, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, DPD)
- DIN
- 02245603
- Trade name
- DAWNMIST
- Company
- DONOVAN INDUSTRIES, INC.
- Current status
- Cancelled after marketing: 30 July 2007
- Product update in the source
- 22 March 2025
- Form
- Pâte dentifrice
- Routes
- Dentaire
- ATC classes
- A01AA02 : French label not published
Status history
- Marketed: 27 February 2002
- Cancelled after marketing: 30 July 2007; current status
Published active ingredients and strengths
| Published active ingredient | Published strength | Percentage conversion |
|---|---|---|
| SODIUM MONOFLUOROPHOSPHATE | 0.76 %; strength expressed as base | 0,76 % (unspecified basis) |
Mass/volume percentages are not treated as mass/mass percentages. A strength expressed as base is not converted to the strength of the salt or compound.
Cosmetic analysis in the European Union
- SODIUM MONOFLUOROPHOSPHATE : Status and conditions in the European annexes below.
- Annexe III, entrée 27 : 0,15 % calculated as F. When mixed with other fluorine compounds permitted under this Annex, total F concentration must not exceed 0,15 % ; seulement pour : Oral products ; comparaison de teneur non établie sans estimation.
1 ingredient allowed under conditions (maximum concentration, product types): some active ingredient concentrations are printed; the other conditions and the product's classification in the European Union remain to be checked. 1 name recognised out of 1.
- Babies and children : Worth watching SODIUM MONOFLUOROPHOSPHATE
Who it concerns
For each group, the ingredients of the list that an official classification or rule mentions. Open an ingredient's page to read what the text says. A group with no name does not mean the ingredients were judged to have no effect for it.
Prohibition or serious classificationThe text prohibits the substance for this use, or ranks it among the most serious hazards (known or presumed carcinogenic, mutagenic or reprotoxic, identified endocrine disruptor).Worth watchingThe text sets a condition or flags a hazard worth knowing: allergen, suspected effect, condition for children, hazard to the aquatic environment.For informationOfficial information with no condition on a finished product: warning to read, irritation of the pure substance.
Babies and children
- Worth watching SODIUM MONOFLUOROPHOSPHATEAnnex III, entry 27, sets a condition for children: “For any toothpaste with compounds containing fluorine in a concentration of 0.1 to 0.15% calculated as F unless it is already labelled as contra-indicated for children (e.g.”
Read on the label
- For information SODIUM MONOFLUOROPHOSPHATEAnnex III, entry 27, requires this to be printed on the pack: “Contains sodium monofluorophosphate For any toothpaste with compounds containing fluorine in a concentration of 0.1 to 0.15% calculated as F unless it is already labelled as contra-indicated for children (e.g. "for adult use only") the following labelling is obligatory: "Children of 6 years and younger: use a pea-sized amount for supervised brushing to minimise swallowing. In case of intake of fluoride from other sources consult a dentist or doctor."”.
No official text covers the recognised ingredients for: pregnancy and breastfeeding, skin, eyes and allergies, environment.
For a question about your own situation (pregnancy, child, allergy), show this list to your doctor, midwife or pharmacist: we cannot say whether this product suits you.
Selling elsewhere
Ingredients of this list that are prohibited, prohibited in some cases or subject to conditions in the other countries whose rules we record (nothing changes for sale in France). Absence is not approval: several countries only allow the preservatives, UV filters and colorants on their lists, and the function of an ingredient in the product is not known. What is covered for each country.
| Country | Prohibited | Prohibited in some cases | Subject to conditions |
|---|---|---|---|
| United Kingdom | - | - | SODIUM MONOFLUOROPHOSPHATE |
| Canada | - | - | SODIUM MONOFLUOROPHOSPHATE |
| ASEAN | - | - | SODIUM MONOFLUOROPHOSPHATE |
| Taiwan | - | - | SODIUM MONOFLUOROPHOSPHATE |
No prohibition or condition found in the recorded lists for: United States (federal), Washington State, California, Japan, South Korea, China, Australia, Brazil.
Ingredient by ingredient
The line under each name gives its rule in the European Union (legend below). Click a name for its page.
Hover over or tap a badge for its meaning.
Classified hazard (cancer, DNA, reproduction): Carcinogenic, mutagenic or toxic for reproduction under the CLPEU regulation that classifies chemicals by their hazards (EC No 1272/2008). Regulation, or identified endocrine disruptor. Irritation, allergy and environment: see “Who it concerns”.
| On the label | Glossary name | Rule in the European Union | Classified hazard (cancer, DNA, reproduction) |
|---|---|---|---|
| SODIUM MONOFLUOROPHOSPHATE | SODIUM MONOFLUOROPHOSPHATE | Allowed with restrictions (Annex III) Annex III, entry 27: products: Oral products; maximum concentration: 0.15% calculated as F. When mixed with other fluorine compounds permitted under this Annex, total F concentration must not exceed 0.15% | none |
Official Drug Product Database record.
Contient des informations visées par la Licence du gouvernement ouvert – Canada (Santé Canada, BDPP).